Why no Bad-Ad Program letters?

OPDP's Bad Ad Program, which launched in May 2010, was meant to help physicians spot misleading drug promotion and offer an easy way to report the activity. But four years on, some question its impact.

While two dozen enforcement letters were sent by FDA's Office of Prescription Drug Promotion to pharma companies last year, up from 21 in 2012, none of the letters were prompted by the Bad Ad Program.

“Have healthcare providers stopped reporting misleading activities to the FDA, or is there another explanation for the decline?” asks Porzio LifeSciences's Kim Capone, a senior regulatory analyst who tabulated the figures, in an April note to the advisory firm's clients.

According to Capone, Bad Ad Program letters peaked in 2011 with five, falling to three in 2012 and none in 2013. Enforcement is but one component of OPDP oversight of prescription drug promotion, an FDA press officer told MM&M. “Therefore, one cannot get a complete picture of OPDP's program area by looking at a snapshot of time for enforcement letters.” Capone was not available at press time.

To raise awareness of the program, the FDA last year launched an e-learning CME/CE course to help HCPs and med students learn to identify prescription drug promotion that may be misleading or raise other regulatory issues and report it, offering several case studies based on enforcement letters.

You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.